Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A5TM
|
||||
| Former ID |
DIB001799
|
||||
| Drug Name |
SGB-1534
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypotension [ICD9: 458, 796.3; ICD10:I95] | Discontinued in Phase 2 | [1] | ||
| Company |
Chugai Pharmaceutical Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H25ClN4O3
|
||||
| Canonical SMILES |
n1(c(=O)[nH]c2c(c1=O)cccc2)CCN1CCN(c2c(OC)cccc2)CC1.Cl
|
||||
| CAS Number |
CAS 88068-72-8
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Alpha-2C adrenergic receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolism | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000148) | ||||
| REF 2 | Potent alpha-adrenoceptor blocking action of SGB-1534, a new quinazoline antihypertensive agent in vitro experiments. Gen Pharmacol. 1986;17(2):143-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.